Laboratorios Clausen S. A. announces the launching of Elaxim (Tenecteplase, recombinant, t-PA).
Elaxim is a third generation tissue plasminogen activator (tPA) produced by recombinant DNA technology, is the only thrombolytic agent that can be administered as a single bolus, injection over 5 to 10 seconds with proven clinical efficacy and safety.
Elaxim is indicated in thrombolytic treatment of the acute phase of myocardial infarction (AMI) for reduction of mortality associated with AMI.
Elaxim is supplied as a sterile, lyophilized powder in a vial under partial vacuum. Each 50mg vial of tenecteplase is packaged with one 10 ml vial of Sterile Water for Injection, for reconstitution.